Affinity Asset Advisors logo

Affinity Asset Advisors

North America, New York, United States, New York

Description

Affinity Asset Advisors is a healthcare-focused hedge fund with public and private investments

Investor Profile

Affinity Asset Advisors has made 10 investments, with 0 in the past 12 months and 20% as lead.

Stage Focus

  • Post Ipo Equity (40%)
  • Series A (20%)
  • Series D (10%)
  • Series C (10%)
  • Series B (10%)
  • Series Unknown (10%)

Country Focus

  • United States (80%)
  • Canada (10%)
  • Singapore (10%)

Industry Focus

  • Biotechnology
  • Therapeutics
  • Health Care
  • Medical
  • Clinical Trials
  • Computer
  • Medical Device
  • Health Diagnostics
  • Neuroscience
  • Oncology
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Affinity Asset Advisors frequently co-invest with?

Access Biotechnology
North America, New York, United States, New York
Co-Investments: 1
Altium Capital
North America, New York, United States, New York
Co-Investments: 2
CA
North America, Massachusetts, United States, Boston
Co-Investments: 1
Braidwell
North America, Connecticut, United States, Stamford
Co-Investments: 2
RTW Investments
North America, New York, United States, New York
Co-Investments: 2
Ally Bridge Group
Asia, Hong Kong Island, Hong Kong, Hong Kong
Co-Investments: 2
Deep Track Capital
North America, Connecticut, United States, Greenwich
Co-Investments: 2
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 2
CC
North America, New York, United States, New York
Co-Investments: 1
Boxer Capital
North America, Florida, United States, Windermere
Co-Investments: 2

What are some of recent deals done by Affinity Asset Advisors?

Spyre Therapeutics

San Francisco, California, United States

Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies.

BiotechnologyTherapeutics
Post Ipo EquityDec 7, 2023
Amount Raised: $180,000,000
Tourmaline Bio

New York, New York, United States

Tourmaline Bio is a clinical biotechnology company developing transformative medicines to dramatically improve and prevent immune diseases.

BiotechnologyClinical TrialsTherapeutics
Post Ipo EquityOct 19, 2023
Amount Raised: $75,000,000
ProMIS Neurosciences

Toronto, Ontario, Canada

ProMIS Neurosciences develops therapeutic products and diagnostic devices targeting misfolded protein diseases.

BiotechnologyHealth DiagnosticsMedicalNeuroscienceTherapeutics
Post Ipo EquityAug 21, 2023
Amount Raised: $20,400,000
Ceptur Therapeutics

Hillsborough, New Jersey, United States

Revolutionizing gene silencing by developing targeted oligonucleotide therapeutics based on U1 Adaptor technology

BiotechnologyMedicalTherapeutics
Series AJan 19, 2022
Amount Raised: $75,000,000
Renovacor

Philadelphia, Pennsylvania, United States

Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.

BiotechnologyHealth CareLife Science
Post Ipo EquitySep 3, 2021
Amount Raised: $30,000,000
Kurome Therapeutics

Cincinnati, Ohio, United States

Kurome Therapeutics is a preclinical stage company focused on subverting cancer's ability to evade therapy.

BiotechnologyHealth CareTherapeutics
Series AJun 10, 2021
Amount Raised: $15,000,000
Hummingbird Bioscience

Woodlands, North Region, Singapore

Hummingbird Bioscience focuses on the discovery and early development of oncology drugs.

BiotechnologyHealth CareOncologyTherapeutics
Series CMay 18, 2021
Amount Raised: $125,000,000
Tesseract Health

Guilford, Connecticut, United States

Tesseract Health provides devices for disease monitoring and prevention.

Health Care
Series BApr 20, 2021
Amount Raised: $80,000,000
Hyperfine

Guilford, Connecticut, United States

Hyperfine makes MRI accessible to every patient regardless of income or resources.

ComputerHealth CareMedical Device
Series DFeb 10, 2021
Amount Raised: $90,000,000
Ceptur Therapeutics

Hillsborough, New Jersey, United States

Revolutionizing gene silencing by developing targeted oligonucleotide therapeutics based on U1 Adaptor technology

BiotechnologyMedicalTherapeutics
Series UnknownAug 13, 2020
Amount Raised: $6,200,000